The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison. Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of participants reporting prespecified local reactions following vaccination
Timeframe: Within 7 days after vaccination
Percentage of participants reporting prespecified systemic events following vaccination.
Timeframe: Within 7 days after vaccination
Percentage of participants reporting adverse events (AEs) following vaccination.
Timeframe: Within 1 month after vaccination
Percentage of participants reporting serious adverse events (SAEs) following vaccination.
Timeframe: Within 6 months after vaccination
Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs) following vaccination.
Timeframe: Within 6 months after vaccination
Pfizer CT.gov Call Center